Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Self-monitoring of blood glucose (SMBG) is a core component of diabetes management. However, the International Diabetes Federation recommends that SMBG be performed in a structured manner and that the data are accurately interpreted and used to take appropriate therapeutic actions. We designed a study to evaluate the impact of structured SMBG on glycemic control in non-insulin-treated type 2 diabetes (T2DM) patients. The Prospective, Randomized Trial on Intensive SMBG Management Added Value in Non-insulin-Treated T2DM Patients (PRISMA) is a 12-month, prospective, multicenter, open, parallel group, randomized, and controlled trial to evaluate the added value of an intensive, structured SMBG regimen in T2DM patients treated with oral agents and/or diet. One thousand patients (500 per arm) will be enrolled at 39 clinical sites in Italy. Eligible patients will be randomized to the intensive structured monitoring (ISM) group or the active control (AC) group, with a glycosylated hemoglobin (HbA1c) target of <7.0%. Intervention will comprise (1) structured SMBG (4-point daily glucose profiles on 3 days per week [ISM]; discretionary, unstructured SMBG [AC]); (2) comprehensive patient education (both groups); and (3) clinician's adjustment of diabetes medications using an algorithm targeting SMBG levels, HbA1c and hypoglycemia (ISM) or HbA1c and hypoglycemia (AC). The intervention and trial design build upon previous research by emphasizing appropriate and collaborative use of SMBG by both patients and physicians. Utilization of per protocol and intent-to-treat analyses facilitates assessment of the intervention. Inclusion of multiple dependent variables allows us to assess the broader impact of the intervention, including changes in patient and physician attitudes and behaviors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961 · cited 1×
“While elevated HbA1c levels are clearly linked with the development and progression of diabetic complications, a growing body of evidence suggests that excessive postprandial glycemic excursions may also be a significant risk factor for both microvascular [8] and macrovascular disease [9–14].”
BackgroundSelf-citationGlobal guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981 · cited 1×
“Large randomized, controlled clinical trials, such as the Diabetes Control and Complication Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), have demonstrated that tight glycemic control reduces the risk of microvascular diabetic complications in both type 1 diabetes (T1DM) [1, 2], and T2DM [3–5…”
MethodHanefeld, M. (2004) · European Heart Journal · doi:10.1016/s0195-668x(03)00468-8 · Cited by 641
Cavalot, F., Petrelli, A., Traversa, M., Bonomo, K., Fiora, E., Conti, M., Anfossi, G., Costa, G., & Trovati, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1005 · Cited by 569
Esposito, K., Giugliano, D., Nappo, F., & Marfella, R. (2004) · Circulation · doi:10.1161/01.cir.0000134501.57864.66 · Cited by 440 · cited 2×
“macrovascular disease [15–17].”
BackgroundPolonsky, W. H., Fisher, L., Schikman, C. H., Hinnen, D. A., Parkin, C. G., Jelsovsky, Z., Petersen, B., Schweitzer, M., & Wagner, R. S. (2011) · Diabetes Care · doi:10.2337/dc10-1732 · Cited by 429
Self-citationFarmer, A., Wade, A., Goyder, E., Yudkin, P., French, D., Craven, A., Holman, R., Kinmonth, A.-L., & Neil, A. (2007) · BMJ · doi:10.1136/bmj.39247.447431.be · Cited by 407
Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1278 · Cited by 406 · cited 1×
“However, in patients with a high cardiovascular risk, an intensive management of diabetes targeting normal glycated hemoglobin (HbA1c) levels with the use of multiple diabetes medications is associated with higher mortality than is a standard approach targeting higher HbA1c levels [6, 7].”
Background
Cited by
Bosi, E., Scavini, M., Ceriello, A., Cucinotta, D., Tiengo, A., Marino, R., Bonizzoni, E., Giorgino, F., & on behalf of the PRISMA Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0092 · Cited by 105
Self-citationMannucci, E., Antenore, A., Giorgino, F., & Scavini, M. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817719290 · Cited by 90
Self-citationSelf-Monitoring of Blood Glucose in Type 2 Diabetes: Recent Studies
Schnell, O., Alawi, H., Battelino, T., Ceriello, A., Diem, P., Felton, A.-M., Grzeszczak, W., Harno, K., Kempler, P., Satman, I., et al. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700225 · Cited by 88
Self-citationGarcía de la Torre, N., Durán, A., del Valle, L., Fuentes, M., Barca, I., Martín, P., Montañez, C., Perez-Ferre, N., Abad, R., Sanz, F., et al. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0467-9 · Cited by 24
Russo, G. T., Scavini, M., Acmet, E., Bonizzoni, E., Bosi, E., Giorgino, F., Tiengo, A., Cucinotta, D., & on behalf of the PRISMA Study Group (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0358 · Cited by 21
“The PRISMA Study protocol has been presented in detail elsewhere.(6) Briefly, the PRISMA Study was a 12-month, prospective, multicenter, open, parallel group, randomized, and controlled trial with the aim of evaluating the added value of an intensive, structured SMBG regimen (intensive structured monitoring [ISM] grou…”
MethodSelf-citation
Metadata
- Authors
- Scavini, M., Bosi, E., Ceriello, A., Giorgino, F., Porta, M., Tiengo, A., Vespasiani, G., Bottalico, D., Marino, R., Parkin, C., Bonizzoni, E., & Cucinotta, D.
- Venue
- Acta Diabetologica
- Published
- 2011-12-22
- Volume
- 50
- Issue
- 5
- Pages
- 663-672
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2077124864
- Cited by
- 25
- References
- 19
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. https://app.cochat.ai/papers/10.1007/s00592-011-0357-y
- The paper
- Scavini, M., Bosi, E., Ceriello, A., Giorgino, F., Porta, M., Tiengo, A., Vespasiani, G., Bottalico, D., Marino, R., Parkin, C., Bonizzoni, E., & Cucinotta, D. (2013). Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. Acta Diabetologica. https://doi.org/10.1007/s00592-011-0357-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.